Table 1.
Characteristics and predisposing conditions in patients with NTM infections (n = 118).
| Underlying immune disease | n | Percentage |
|---|---|---|
| Immunocompetent | 54 | 45.8% |
| Immunocompromised | 64 | 54.2% |
| AIDS | 4 | 3.4% |
| Rheumatic autoimmune diseases | ||
| SLE | 5 | 4.3% |
| RA | 4 | 3.4% |
| Vasculitis | 5 | 4.3% |
| PM/DM | 1 | 0.8% |
| SSc | 2 | 1.7% |
| Overlap syndrome | 1 | 0.8% |
| pSS | 2 | 1.7% |
| Ankylosing spondylitis | 1 | 0.8% |
| Relapsing polychondritis | 1 | 0.8% |
| Anti-synthetase antibody syndrome | 1 | 0.8% |
| Malignancy | ||
| Solid-organ malignancy in chemotherapy | 4 | 3.4% |
| Haematologic malignancy | 5 | 4.3% |
| Others under continuous corticosteroid (>3 months or high-dose > 0.5 mg/kg/day) or immunosuppressive therapy | 18 | 15.3% |
| Primary immunodeficiency diseases | ||
| Cellular immune dysfunction | 3 | 2.5% |
| Adult-onset immunodeficiency | 5 | 4.3% |
| MonoMAC syndrome | 1 | 0.8% |
| Hypoimmunoglobulinemia | 1 | 0.8% |
AIDS, acquired immunodeficiency syndrome; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; PM, polymyositis; DM, dermatomyositis; SSc, systemic sclerosis; Overlap syndrome, includes features of SSc and PM; pSS, primary Sjögren syndrome.